MEM 1414

Drug Profile

MEM 1414

Alternative Names: R 1533

Latest Information Update: 29 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memory Pharmaceuticals
  • Developer Roche
  • Class Antidementias; Antidepressants; Nootropics; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Allergic asthma; Alzheimer's disease; Major depressive disorder; Mild cognitive impairment

Most Recent Events

  • 29 Mar 2010 No development reported - Phase-I for Alzheimer's disease in USA (PO)
  • 29 Mar 2010 No development reported - Phase-I for Mild cognitive impairment in USA (PO)
  • 29 Mar 2010 No development reported - Phase-II for Allergic asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top